Cargando…
What can we do about osteoarthritis?
Osteoarthritis is complex in genetics, pathogenesis, monitoring and treatment. Current treatment of osteoarthritis does not influence progression. Much could be gained by more effective 'low-tech-low-cost' treatment. However, many patients have rapidly progressive disease, multiple joint i...
Autor principal: | |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2000
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC129992/ https://www.ncbi.nlm.nih.gov/pubmed/11094419 http://dx.doi.org/10.1186/ar74 |
_version_ | 1782120367716827136 |
---|---|
author | Lohmander, L Stefan |
author_facet | Lohmander, L Stefan |
author_sort | Lohmander, L Stefan |
collection | PubMed |
description | Osteoarthritis is complex in genetics, pathogenesis, monitoring and treatment. Current treatment of osteoarthritis does not influence progression. Much could be gained by more effective 'low-tech-low-cost' treatment. However, many patients have rapidly progressive disease, multiple joint involvement, and severe disease. We need to clarify the genetics of osteoarthritis, identify those at risk for progression and severe disease, and identify molecular processes critical for joint survival and failure. Will saving the cartilage improve patient pain and function? Effective outcome measures are needed to accelerate testing of new treatments. Further improvement is needed in joint implant technology to decrease costs, wear and loosening. |
format | Text |
id | pubmed-129992 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2000 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-1299922002-10-28 What can we do about osteoarthritis? Lohmander, L Stefan Arthritis Res Commentary Osteoarthritis is complex in genetics, pathogenesis, monitoring and treatment. Current treatment of osteoarthritis does not influence progression. Much could be gained by more effective 'low-tech-low-cost' treatment. However, many patients have rapidly progressive disease, multiple joint involvement, and severe disease. We need to clarify the genetics of osteoarthritis, identify those at risk for progression and severe disease, and identify molecular processes critical for joint survival and failure. Will saving the cartilage improve patient pain and function? Effective outcome measures are needed to accelerate testing of new treatments. Further improvement is needed in joint implant technology to decrease costs, wear and loosening. BioMed Central 2000 2000-02-18 /pmc/articles/PMC129992/ /pubmed/11094419 http://dx.doi.org/10.1186/ar74 Text en Copyright © 2000 Current Science Ltd |
spellingShingle | Commentary Lohmander, L Stefan What can we do about osteoarthritis? |
title | What can we do about osteoarthritis? |
title_full | What can we do about osteoarthritis? |
title_fullStr | What can we do about osteoarthritis? |
title_full_unstemmed | What can we do about osteoarthritis? |
title_short | What can we do about osteoarthritis? |
title_sort | what can we do about osteoarthritis? |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC129992/ https://www.ncbi.nlm.nih.gov/pubmed/11094419 http://dx.doi.org/10.1186/ar74 |
work_keys_str_mv | AT lohmanderlstefan whatcanwedoaboutosteoarthritis |